Prism MarketView

What’s Behind the Sudden Surge in Snowflake $SNOW Shares Today? https://lnkd.in/gTucc6_h Listen to The Prism MarketView Podcast Report: https://lnkd.in/gaFvA-e9

Marijuana Milestone: FDA Approves Trial to Assess Smoked Medical Cannabis to Treat PTSD For Veterans The U.S. Food and Drug Administration (FDA) has?approved a significant clinical trial?to assess the effectiveness of smoked medical marijuana in treating post-traumatic stress disorder (PTSD) among military veterans. This approval marks a pivotal step in exploring cannabis as a potential therapeutic option for PTSD, a condition that affects many veterans. The study is led by the Multidisciplinary Association for Psychedelic Studies (MAPS) who aims to provide comprehensive data on the safety and efficacy of smoked cannabis for PTSD symptoms. MAPS has been at the forefront of research into psychedelic substances and cannabis for therapeutic purposes. This development follows a series of legislative efforts to facilitate cannabis research for veterans. Earlier this year, the Senate Veterans Affairs Committee approved a bipartisan bill to promote marijuana research for military veterans, highlighting the growing interest in alternative treatments for PTSD and chronic pain. The FDA’s approval of this trial represents a significant advancement in the pursuit of alternative therapies for PTSD, offering hope for veterans seeking new treatment options. #FDA #MedicalMarijuana #MAPS #PTSD #PrismMartketView #PrismMediaWire #PrismDigitalMedia https://lnkd.in/ge-WNnV6

Matt Gaetz Withdraws from Attorney General Consideration Former Rep. Matt Gaetz (R-Fla.) announced Thursday that he is withdrawing his name from consideration for President-elect Donald Trump’s nomination as attorney general. In a statement posted on X, Gaetz expressed gratitude for the support he received but cited concerns that his confirmation process was becoming a distraction to the Trump transition team. Gaetz emphasized the urgency of having a fully operational Department of Justice on Day 1 of the new administration, stating, “There is no time to waste on a needlessly protracted Washington scuffle.” He reaffirmed his commitment to supporting Trump’s presidency and expressed gratitude for the nomination, calling it a great honor. The decision comes as Trump continues to assemble his cabinet and prepare for his administration’s priorities. Gaetz, a vocal Trump ally, had been a polarizing figure, with his potential nomination drawing both strong support and significant opposition. #MattGaetzWithdraws #USAttorneyGeneral #PoliticalNews https://lnkd.in/gNNiXyyA

Cerence Inc. Bets Big on Generative AI, Stock Skyrockets 80% on 2025 Profitability Vision Cerence Inc. (NASDAQ: $CRNC), a leader in automotive artificial intelligence, announced a major strategic pivot towards generative AI during its Q4 2024 earnings call. The company aims to achieve profitability by fiscal year 2025, under the leadership of recently appointed CEO Brian Krzanich. In Q4, Cerence exceeded revenue guidance, reporting $54.8 million, with an adjusted EBITDA of negative $1.9 million—better than expected. Full-year revenue reached $331.5 million, bolstered by 10 new customer wins and the launch of six generative AI solutions tailored for automotive voice interactions. Strategic partnerships with Volkswagen, ( $VWAGY), Renault, and BMW underscore the company’s ambitious generative AI strategy. Cerence forecasts 2025 revenue of $236-247 million, adjusted EBITDA of $15-26 million, and free cash flow of $20-30 million, signaling a sharp focus on profitability. Cost reductions aimed at saving $35-40 million are already underway. Key Highlights: Q4 Revenue: $54.8 million, exceeding guidance. Customer Wins: 10 new deals and 6 generative AI solutions launched. Profitability Goal: Fiscal 2025 with projected EBITDA of $15-26 million. Beyond automotive, Cerence is exploring new markets such as wearable technology and home entertainment, positioning itself as an AI innovator. The stock has surged 80% on optimism around its strategic shift and future outlook. #stockstowatch #stocksinnews #investors #daytrader #PrismMartketView #PrismMediaWire #PrismDigitalMedia #CerenceInc #CRCN #VWAGY #AutomotiveAI https://lnkd.in/gt-ECjYE

All Aboard The AI Train: NVIDIA CEO States “The Age of Generative AI Is In Full Steam” in Record Q3 Report The third quarter was another record quarter for NVIDIA ( $NVDA), with revenue of $35.1Bn, up 17% sequentially and 94% year-over-year (y/y). All market platforms posted strong sequential and y/y growth, driven by the adoption of NVIDIA’s accelerated computing and AI. In the data center segment, revenue reached a record $30.8Bn, up 17% sequentially and 112% y/y. Cloud service providers were approximately half of data center sales, with revenue increasing more than 2x y/y as they deployed NVIDIA H200 infrastructure and high-speed networking. NVIDIA’s inference platform also saw significant growth, with rapid advancements in software algorithms boosting inference throughput by 5x in one year. For Q4, NVIDIA expects total revenue of $37.5 billion, plus or minus 2%, driven by continued demand for Hopper architectures and the initial ramp of Blackwell. GAAP and non-GAAP gross margins are expected to be 73% and 73.5%, respectively, plus or minus 50 basis points. As Blackwell ramps, gross margins are expected to moderate to the low 70s when fully ramped, with Blackwell margins in the mid-70s. After a successful mass ramp, the Blackwell AI infrastructure is now in full production, with 13,000 GPU samples shipped to customers in Q3, including the first Blackwell DGX engineering samples. Blackwell is a full-stack, full-infrastructure AI data center system with customizable configurations to address a diverse and growing market. Demand for Blackwell is staggering, and NVIDIA is racing to scale supply to meet the incredible demand. Blackwell is now in the hands of all major partners, who are working to bring up their data centers. Customers like Oracle, Microsoft, and Google are gearing up to deploy Blackwell at scale, with Oracle announcing the world’s first zettascale cloud computing clusters that can scale to over 131,000 Blackwell GPUs. Additionally, Nvidia sees continued strong demand for its Hopper architecture, with the H200 being the fastest growing and ramping product the company has seen. Hopper sales are expected to continue in Q4 alongside the Blackwell ramp. The company is facing supply constraints in its gaming business, which is expected to result in a sequential decline in gaming revenue in Q4. However, Nvidia expects to be “back on track with more supply” as it turns the corner into the new calendar year. READ MORE https://lnkd.in/g9az9fd8 #stockstowatch #stocksinnews #investors #daytrader #PrismMartketView #PrismMediaWire #PrismDigitalMedia #NVIDIA #NVDA

Lipella Pharmaceuticals ($LIPO) Completes Dosing of First Cohort in Phase 2a Trial of LP-310; Top-Line Data Expected by Year-End Today the clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, Lipella Pharmaceuticals Inc. (LIPO) announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). First Dosing of Phase 2a Trial Highlights: Eight participants received a dose of 0.25 mg LP-310, with promising initial results and no product-related serious adverse events reported. Pharmacokinetic data demonstrated that whole blood tacrolimus levels in all patients were either undetectable or minimal, highlighting LP-310’s potential to deliver localized therapeutic effects while minimizing systemic exposure. All patients tolerated LP-310 without significant adverse reactions. Following a successful internal safety evaluation of the first dose cohort, the trial has received approval to proceed to the next stage of the trial. This stage will evaluate a higher dose of 0.5 mg of LP-310. Janet Okonski, Director of Clinical Operations at Lipella Pharmaceuticals, noted feedback from the study site, stating, “The tolerability observed in this initial cohort is a promising indicator. Oral Lichen Planus severely affects patient quality of life, and an effective, well-tolerated treatment is desperately needed. It’s encouraging to see this kind of response at an early stage.” The company’s dedication to developing a safe and effective therapy for Oral Lichen Planus patients continues to be persistent as they begin to activate additional sites and begin enrolling the next dose cohort. The pace of Lipella’s promising progress puts them on track to deliver top-line data by year-end and complete the trial by mid-2025. About Oral Lichen Planus (OLP) Oral Lichen Planus (OLP) is a chronic inflammatory condition that affects the mucous membranes inside the mouth, which can cause pain and make eating, drinking and even speaking uncomfortable. Characterized by symptoms such as burning pain, white patches, swollen tissue, and open sores, OLP impacts approximately 6 million Americans and currently has no FDA-approved therapies. #stockstowatch #stocksinnews #investors #daytrader #PrismMartketView #PrismMediaWire #PrismDigitalMedia #OralLichenPlanus #OLP #LipellaPharma https://lnkd.in/ebUrrmym

Bill Hwang Sentenced to 18 Years at the Crow Bar Hotel—Fair Punishment or Too Harsh? Share your thoughts on the $10B Archegos collapse #Finance #Justice #Fraud https://lnkd.in/eMQ4_6m9

Forte Biosciences (NASDAQ: $FBRX)Secures $53 Million to Fast-Track Breakthrough Autoimmune Therapy; Stock Soars 137% Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company specializing in autoimmune diseases, has raised $53 million in an oversubscribed private placement. The funds will support the continued development of FB102, Forte's leading therapeutic candidate targeting a broad range of autoimmune and related conditions. The financing drew participation from top-tier healthcare institutional investors, including OrbiMed, Janus Henderson Investors, and Tybourne Capital Management. This significant capital injection positions Forte to advance FB102 into additional clinical trials over the next year, with celiac disease trials currently underway and topline data expected in Q2 2025. Forte's CEO, Paul Wagner, Ph.D., highlighted the transformative impact of the financing, emphasizing its importance in achieving critical clinical milestones in 2025. The company plans to share further details at its upcoming R&D Day on December 3rd. TD Cowen led the placement, with support from Guggenheim Securities and co-placement managers Chardan, Rodman & Renshaw, and Brookline Capital Markets. FB102, an anti-CD122 monoclonal antibody, is central to Forte’s efforts to address unmet needs in autoimmune diseases, with promising potential across multiple indications. #ForteBiosciences #AutoimmuneTherapy #AutoimmuneDisease #stockstowatch #stocksinnews #investors #daytrader #PrismMarketView #PrismMediaWire #PrismDigitalMedia #ForteBiosciences https://lnkd.in/eqJ-GFuk

Comcast ($CMCSA) Spins Off Major Cable Networks As Pressures From Streaming Services Impact Traditional Cable Providers Today Comcast (CMCSA) announced plans to spin off the majority of its cable television networks into a new publicly traded company. The spin-off, temporarily named “SpinCo,” will include popular channels like USA Networks, CNBC, MSNBC, Oxygen network, E -TV network!, SyFy Channel, and Golf Channel. However, Comcast will retain key NBCUniversal assets, including NBC’s broadcast network, NBC News, NBC Sports, the streaming platform Peacock, and the cable channel Bravo. Mark Lazarus, chairman of NBCUniversal’s media group, will lead SpinCo as its CEO, with Anand Kini serving as CFO and COO. The tax-free structured spin off transition to shareholders, is expected to take about a year to complete, according to Comcast President Mike Cavanagh. He emphasized that SpinCo will be well-capitalized, with strong cash flow, a solid balance sheet, and the financial flexibility to pursue growth through organic initiatives or acquisitions. This decision comes as a response to Comcast’s shifts in the media industry. Hurdles have been faced by traditional cable providers from cord-cutting and the rise of streaming services. Traditional cable TV has faced declining subscriptions, even as some channels remain profitable. Comcast’s streaming service, Peacock, continues to grow, adding 3M subscribers in the last fiscal quarter, despite losing 365K cable customers in the same period. Management believes the well-capitalized, independent company will hold the potential to lead the changing landscape for cable networks and feels confident in the strength of SpinCo’s portfolio and leadership team. Comcast’s stock price rose in premarket trading after the announcement and shares remain slightly in the green. Dan Ives, a technology sector analyst at Wedbush Securities, called the spin-off a “smart strategic move,” citing the potential for new monetization strategies in the evolving cable and streaming markets. #stockstowatch #stocksinnews #investors #daytrader #PrismMarketView #PrismMediaWire #Comcast #ComcastPeacock #streaming #PrismDigitalMedia https://lnkd.in/eC4SEZdR

.@Bitcoin ( $BTC-USD) #BTC has hit a record high above $94,000. Are you riding the Crypto wave? #RideTheCryptoWave #Crypto #BTC #BitCoin #stockstowatch #stocksinnews #investors #daytrader #PrismMarketView #PrismMediaWire #PrismDigitalMedia